Tirzepatide denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Tirzepatide as Not Medically Necessary — and Why You Can Appeal

Medical-necessity denials for tirzepatide from UnitedHealthcare are among the most common and most successfully appealed denial types. UHC applies a clinical coverage policy that sets out specific eligibility criteria — diagnosis requirements, clinical severity markers, prior-treatment history, and documentation standards. A denial often means the submitted documentation did not clearly demonstrate that each criterion was met, not necessarily that your case fails to qualify.

## Why This Denial Is Appealable

Medical-necessity determinations must be based on the individual patient's clinical circumstances, not on a blanket policy applied without individualized review. Under ERISA and ACA standards, UHC's reviewing clinician must consider your specific chart data. If the denial letter cites missing documentation rather than a clinical finding, the appeal path is straightforward: supply the missing documentation. If UHC's reviewer reached a different clinical conclusion than your prescriber, an external review by an independent clinician adds a second medical opinion that frequently overturns the denial.

## Federal Appeal Framework

• Internal appeal: ERISA §503 (employer plans) guarantees a full-and-fair internal review. File within the deadline on your denial notice — typically 180 days. You are entitled to the clinical criteria and rationale UHC used.
• External review: Under ACA §2719, after exhausting internal remedies you may request independent external review. The window is generally within approximately four months of the final internal denial. External reviewers are clinicians with no financial relationship to UHC.
• Expedited review: If delay would seriously jeopardize your health or ability to function, expedited internal and external review are both available, with typical decisions within 72 hours.

## Concrete Appeal Steps

1. Obtain the denial letter and request UHC's clinical coverage policy for tirzepatide — you are entitled to the exact criteria applied. 2. With your prescriber, go through each criterion and confirm your chart contains evidence satisfying it. 3. Have your prescriber write a detailed medical-necessity letter specifically addressing each policy criterion. 4. Compile the full documentation package below and submit your internal appeal. 5. If denied internally, file for external review — independent clinicians frequently overturn medical-necessity denials for well-documented cases.

## Documentation to Gather

• Diagnosis confirmation: Chart notes clearly documenting the qualifying diagnosis (obesity, type 2 diabetes, or both as applicable) with clinical severity indicators your provider has recorded.
• Clinical severity records: Relevant objective data from the chart — weight history, metabolic markers, comorbidity documentation — as documented by your treating clinician.
• Prior treatment history: Dates, agents, and outcomes of prior pharmacological and non-pharmacological treatments tried before tirzepatide, demonstrating a meaningful treatment history.
• Prescriber medical-necessity letter: A detailed letter tying each UHC policy criterion to a specific chart finding, written and signed by your prescribing clinician.
• Applicable guideline reference: Prescriber should cite the relevant guideline organization (e.g., ADA Standards of Care, relevant obesity-medicine society) to establish standard-of-care basis.

## Criteria-Mapping Structure

Copy each numbered or bulleted requirement from UHC's tirzepatide coverage policy into a two-column table. The right column should cite the specific chart fact, lab result, or prescriber attestation that satisfies that criterion. Include the chart page or date reference for each entry. This structure prevents UHC from conducting a de novo review on appeal and forces engagement with your specific evidence.